TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GT Biopharma ( (GTBP) ) just unveiled an announcement.
In September 2025, GT Biopharma, Inc. announced that holders of its Series L 10% Convertible Preferred Stock agreed to waive their redemption rights as outlined in the Certificate of Designations. This waiver could potentially impact the company’s financial flexibility and investor relations by altering the terms under which these securities operate.
The most recent analyst rating on (GTBP) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on GT Biopharma stock, see the GTBP Stock Forecast page.
Spark’s Take on GTBP Stock
According to Spark, TipRanks’ AI Analyst, GTBP is a Underperform.
GT Biopharma’s overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.
To see Spark’s full report on GTBP stock, click here.
More about GT Biopharma
Average Trading Volume: 215,715
Technical Sentiment Signal: Sell
Current Market Cap: $2.85M
For an in-depth examination of GTBP stock, go to TipRanks’ Overview page.